Emergent BioSolutions, Inc., presents positive data for TRU-016

Emergent BioSolutions, Inc. recently announced the presentation of positive data from its Phase I dose escalation study of TRU-016 at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

Results from the study show that TRU-016 demonstrates favorable response rates and is well-tolerated in patients suffering from chronic lymphocytic leukemia. TRU-016 is the company’s humanized anti-CD37 candidate and is being worked on in cooperation with Abbott for the treatment of B-cell malignancies such as non-Hodgkins lymphoma and CLL.

The data on the successful escalation study was presented by Richard Furman, the director of the CLL Research Center at Weill Medical College of Cornell University.

“Despite the many different therapies available for patients with CLL, almost all patients will relapse and die of their disease,” Dr. Furman said. “Novel agents that are more effective and better tolerated are needed to help transform CLL into a truly chronic condition. Of the therapeutics currently in development, targeting CD37 with TRU-016 appears to be among the most promising. TRU-016 is a potent inducer of apoptosis and Fc dependent cellular cytotoxicity of CLL cells. TRU-016’s favorable toxicity profile and preliminary evidence of efficacy in patients warrants further evaluation in combination with other agents.”

Emergent BioSolutions, Inc., plans to continue conducting studies on TRU-016.

“Based on favorable results observed to date, Emergent and our development partner Abbott are in the process of initiating additional combination studies of TRU-016 in CLL and NHL,” Dr. W. James Jackson, chief scientific officer at Emergent BioSolutions, said. “We remain hopeful that TRU-016 could play a meaningful role in improving disease outcomes and quality of life, either on its own or in combination with other therapies.”